Gilead Sciences’ GILD experimental coronavirus candidate, Veklury (remdesivir), has been recommended for approval by the  European Medicines Agency (EMA)’s human medicines committee (CHMP).The CHMP has recommended granting a conditional marketing authorization to Veklury for the treatment of COVID-19 in adults and adolescents from 12 years of age with pneumonia who require supplemental oxygen.Incyte INCY initiated RUXCOVID, a global, randomized, double-blind, placebo-controlled phase III study, evaluating the efficacy and safety of Jakafi plus SoC in patients 12 years and above with COVID-19-associated cytokine storm.